Literature DB >> 1533267

A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium.

J M Soleilhac1, E Lucas, A Beaumont, S Turcaud, J B Michel, D Ficheux, M C Fournié-Zaluski, B P Roques.   

Abstract

Neutral endopeptidase 24.11 (EC 3.4.24.11) inactivates atrial natriuretic peptide by cleaving the hormone between Cys7 and Phe8, and inhibitors of the enzyme have consequent natriuretic and diuretic properties. The in vivo sites of degradation of this peptide by the zinc-metallopeptidase, however, remain to be established. Because an endopeptidase-24.11-like activity has recently been reported in the rat mesenteric artery, we have further investigated the degradation of atrial natriuretic peptide in vascular tissue. Endopeptidase-24.11 activity was detected in solubilized membrane preparations from rat and rabbit vascular tissue, using [3H]D-Ala2-leucine enkephalin as substrate, and both rabbit and rat aorta preparations were also found to cleave atrial natriuretic peptide between Cys7 and Phe8. In both cases, hydrolysis was inhibited by neutral endopeptidase inhibitors, with Ki values close to their Ki values for the pure enzyme. In preparations of rabbit aorta denuded of endothelium by saponin treatment, the hydrolysis of the Gly3-Phe4 bond of [3H]D-Ala2-leucine enkephalin and the Cys7-Phe8 bond of atrial natriuretic peptide was reduced by greater than 90%. The high performance liquid chromatography method used to follow the degradation of atrial natriuretic peptide differed from previously published procedures, in that samples to be injected were first treated with excess dithiothreitol to reduce the Cys7-Cys23 disulfide bridge. This facilitated the separation of the intact peptide and its metabolites. The presence of the 94-kDa neutral endopeptidase in rabbit aortic tissue was definitively established using a new potent 125I-labeled inhibitor, [125I]RB104 [2-[(3-[125I]iodo-4-hydroxy)phenylmethyl]-4-N-[3- hydroxyamino-3-oxo-1-phenylmethyl propyl]amino-4-oxobutanoic acid] (Ki, 30 pM), which selectively labeled the enzyme after sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the membrane preparations. Therefore, despite its low concentrations in the vasculature, the presence of endopeptidase-24.11 almost exclusively in endothelial tissue suggests that the enzyme is ideally localized to inactivate circulating atrial natriuretic peptide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533267

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide.

Authors:  J Peyroux; F Beslot; N Claperon; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 2.  B-type natriuretic Peptide and the right heart.

Authors:  Lok Bin Yap
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

3.  Bradykinin potentiation by ACE inhibitors: a matter of metabolism.

Authors:  Beril Tom; Andreas Dendorfer; René de Vries; Pramod R Saxena; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

4.  Antigenicity and conformational analysis of the Zn(2+)-binding sites of two Zn(2+)-metalloproteases: Leishmania gp63 and mammalian endopeptidase-24.11.

Authors:  K P Soteriadou; A K Tzinia; E Panou-Pamonis; V Tsikaris; M Sakarellos-Daitsiotis; C Sakarellos; Y Papapoulou; R Matsas
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

5.  Serum levels of natriuretic peptides in patients with Behcet's disease.

Authors:  Ramazan Yağci; Yüksel Totan; Ekin Ozlük; Hüseyin Ozyurt; Gülfer Akbay; Meral Ekşioğlu
Journal:  Clin Rheumatol       Date:  2008-04-15       Impact factor: 2.980

6.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

7.  B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.

Authors:  Lena Jafri; Waqar Kashif; Javed Tai; Imran Siddiqui; Iqbal Azam; Hira Shahzad; Farooq Ghani
Journal:  BMC Nephrol       Date:  2013-05-31       Impact factor: 2.388

8.  Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis.

Authors:  R S Baliga; C J Scotton; S L Trinder; R C Chambers; R J MacAllister; A J Hobbs
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.